TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01112852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoloc 40 mg
Description: pantoloc iv. infusion per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatostatin or terlipressin
Description: Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
Study: NCT04780854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants in the intervention group will be administered metformin tablets 2 gm daily during the chemotherapy treatment duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will be administered metformin free tablet as placebo twice daily
Study: NCT04714996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES-481
Description: Treatment Period Week 1 - 25 mg qd, Week 2 - 25 mg bid, Week 3 - 50 mg bid, Week 4 - 75 mg bid.~Step-down and Washout Period Day 1 - 125 mg, Day 2 - 100 mg, Day 3 - 75 mg, Day 4 - 50 mg, Day 5 - 50 mg, Day 6 - 25 mg, Day 7 - 25 mg, Days 8 to 14 - 0 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo on Week 1, Week 2, Week 3 and Week 4
Study: NCT02913300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine 1% concentration solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine 2% concentration solution
Study: NCT02355106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PolarStart System
Description: Atrial flutter Ablation
Study: NCT02033174

Intervention type: OTHER
Group type: OTHER
Intervention: Oral fat diet plus water with sugar
Description: All participants were assigned to receive and oral fat diet plus sugar water. Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. Sugar water has equivalent caloric intakes as alcoholic beverages.

Intervention type: OTHER
Group type: OTHER
Intervention: Oral fat diet plus water with sugar
Description: All participants were assigned to receive and oral fat diet plus sugar water. Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. Sugar water has equivalent caloric intakes as alcoholic beverages.
Study: NCT02207257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Study: NCT02033174

Intervention type: OTHER
Group type: OTHER
Intervention: Oral fat diet plus alcoholic beverages
Description: Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. In all cases, alcohol represented a daily total amount of 16 g/m2. The content of alcohol was 12% in red wine, 37% in rum, and 35% in brandy.Vodka was tri-distilled and contained 40% alcohol.

Intervention type: OTHER
Group type: OTHER
Intervention: Oral fat diet plus alcoholic beverages
Description: Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. In all cases, alcohol represented a daily total amount of 16 g/m2. The content of alcohol was 12% in red wine, 37% in rum, and 35% in brandy.Vodka was tri-distilled and contained 40% alcohol.
Study: NCT02135666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.
Study: NCT00488969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified-release morphine
Description: During the first three weeks of each treatment (drug or placebo), the dose will be escalated toward a maximally tolerated dose or a dose sufficient to eliminate pain (up to a ceiling dose of 120 mg), whichever is reached first. During the entire fourth and fifth week of each period, subjects will receive their maximally tolerated dose of study medication. During the sixth and seventh weeks, they will undergo a seven-day dose tapering and a seven-day complete washout of the study drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modified-release morphine
Description: During the first three weeks of each treatment (drug or placebo), the dose will be escalated toward a maximally tolerated dose or a dose sufficient to eliminate pain (up to a ceiling dose of 120 mg), whichever is reached first. During the entire fourth and fifth week of each period, subjects will receive their maximally tolerated dose of study medication. During the sixth and seventh weeks, they will undergo a seven-day dose tapering and a seven-day complete washout of the study drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00853957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/Amlodipine
Description: Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 mg titrated to 10mg
Study: NCT02644980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index Monitor
Description: BIS monitored from beginning of anesthesia induction to the end of the surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index Monitor
Description: BIS monitored from beginning of anesthesia induction to the end of the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction of anesthesia
Description: Midazolam 0.03 mg/kg injection vein，Sufentanyl 0.5\~1 μg/kg, target controlled infusion of etomidate or propofol,after the consciousness of patients is lost, rocuronium 0.6mg/kg is given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction of anesthesia
Description: Midazolam 0.03 mg/kg injection vein，Sufentanyl 0.5\~1 μg/kg, target controlled infusion of etomidate or propofol,after the consciousness of patients is lost, rocuronium 0.6mg/kg is given.
Study: NCT03020771

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: KIRIM-KONGO-VAX
Description: Crimean-Congo Hemorrhagic Fever Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: KIRIM-KONGO-VAX
Description: Crimean-Congo Hemorrhagic Fever Vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02471040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-hydroxybutyrate
Description: Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-hydroxybutyrate
Description: Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
Study: NCT01395407

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery dose escalation
Description: Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Cohort B: resection cavity volume \> 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume \> 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)~Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)~1. 21 18 15~2. 23 20 17~3. 25 22 19

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery dose escalation
Description: Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Cohort B: resection cavity volume \> 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume \> 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)~Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)~1. 21 18 15~2. 23 20 17~3. 25 22 19

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery dose escalation
Description: Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Cohort B: resection cavity volume \> 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume \> 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)~Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)~1. 21 18 15~2. 23 20 17~3. 25 22 19
Study: NCT04029818

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bifidobacterium BSL_PS404
Description: Each participant will consume 1 capsule daily at lunch for 8 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 1 capsule daily at lunch for 8 weeks.
Study: NCT01966445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2849330
Description: Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2849330
Description: Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion
Study: NCT01878994

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counselling group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nereu group
Study: NCT04106102

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcramial Direct current stimulation
Description: Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder
Study: NCT02644980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance of anesthesia
Description: After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance of anesthesia
Description: After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.
Study: NCT04106102

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder without direct current. They xwill just wear electrodes.
Study: NCT01369186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: i.v. bolus injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: i.v. bolus injection
Study: NCT00821912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
Study: NCT02644980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tracheal Intubation
Description: After the induction of anesthesia, Tracheal intubation is performed.
Study: NCT04067778

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Standard colonoscopy with targeted biopsies only

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Control Group
Description: Standard colonoscopy with random AND targeted biopsies
Study: NCT03594214

Intervention type: DIAGNOSTIC_TEST
Intervention: serum vitamin d level measured by ELISA kit
Description: serum vitamin d level will be measured by a blood sample from newly diagnosed breast cancer patients just after diagnosis (either by surgery specimen or FNA or excisional biopsy specimen) and before receiving any type of treatment for breast cancer
Study: NCT04357977

Intervention type: DIAGNOSTIC_TEST
Intervention: RBA-2
Description: Collection of non-invasive in vivo saliva from confirmed cases of both infected and non-infected COVID-19 patients or site staff at the testing site and compare the test results using the RBA-2 against the standard test results used for diagnosis.
Study: NCT02463864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention exercise
Description: Twice daily, individual, targeted, strengthening, balance and endurance exercises for the duration of the hospital stay, prescribed and delivered by a senior physiotherapist.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Exercise
Description: Twice daily stretching and relaxation exercises for the duration of the hospital stay, by a senior physiotherapist.
Study: NCT01165970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glandosane
Description: according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saliva natura
Description: Saliva substitute without restriction to be used
Study: NCT02179814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMPT/ Demser
Description: alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
Study: NCT02551705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional Imaging
Description: Brain responses associated with emotional memory will be investigated

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: functional Imaging
Description: Brain responses associated with emotional memory will be investigated
Study: NCT03559296

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic assessment of postmastectomy lymphedema
Description: Qualitative assessment of postmastectomy lymphedema via ultrasound (Subcutaneous echogenicity (SEG) and subcutaneous echo-free space (SEFS) grade systems for postmastectomy lymphedema) and circumferential tape measures ( The circumferential measurement of affected arm at MCP joint, wrist joint, 15 below elbow joint, elbow joint 15cm above elbow point) to assess upper extremity volume
Study: NCT02179814

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine (25mg) at the first medication intake time point

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo at the second, third and fourth medication intake time point
Study: NCT04321109

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allograft
Description: Corticocancellous mineralized allograft

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collagen cone
Description: Collagen matrix
Study: NCT00803985

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Extraperitoneal repair (TEP)
Description: Operation for primary inguinal hernias i men

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein
Description: Operation for primary inguinal hernias i men
Study: NCT02819609

Intervention type: PROCEDURE
Intervention: myomectomy
Description: Myomectomy as part of routine clinical care

Intervention type: PROCEDURE
Intervention: endometrial ablation
Description: Endometrial ablation as part of routine clinical care

Intervention type: PROCEDURE
Intervention: uterine artery embolization
Description: Uterine artery embolization as part of routine clinical care

Intervention type: PROCEDURE
Intervention: MRI-guided focused ultrasound ablation
Description: MRI-guided focused ultrasound ablation as part of routine clinical care
Study: NCT01276002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreatic duct stenting
Description: in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.
Study: NCT00747409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart and detemir (NovoRapid, Levemir)
Description: use of basal-bolus therapy with insulin aspart and detemir
Study: NCT02926313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Seating provision
Description: Seating system selected and adjusted to meet individual needs.
Study: NCT00747409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human regular insulin and NPH insulin (Actrapid, Protaphne)
Description: basal-bolus therapy with human regular and NPH insulin
Study: NCT04452773

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Manremyc
Description: Manremyc is composed by 10E5 heat-inactivated Mycobacterium s. manresensis bacilli

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same excipients than active arm without bacilli.
Study: NCT02488746

Intervention type: DEVICE
Intervention: GERDX(TM)
Description: Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
Study: NCT02350738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Period I MCET (8 wks)
Description: MCET_Mock group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk) Mock_MCET group: mock-therapy (3 sessions/wk)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout (4 wks)
Description: 4 weeks wash-out period in both arms and cross-over

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout (4 wks)
Description: 4 weeks wash-out period in both arms and cross-over

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Period II MCET (8 wks)
Description: MCET_Mock group: mock therapy (MCET) (3 sessions/wk) Mock_MCET group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk)
Study: NCT03562468

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg/day of TRU NIAGEN (nicotinamide riboside)
Description: Treatment with 300 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1000 mg/day of TRU NIAGEN (nicotinamide riboside)
Description: Treatment 1000 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo capsules will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
Study: NCT02557984

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: 400 mg Amisulpride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 50 mg Naltrexone
Study: NCT03031119

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered once or twice daily, with food, in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919
Description: Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919
Description: Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.
Study: NCT01278082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
Study: NCT03639142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prunus domestica
Description: Patients will receive prunes at dose 3,5 g/kg/d (max.100mg/day) in three portions a day, for 4 weeks (amount of prescribed prunes will be calibrated with the weight that child ought to have on WHO growth charts at 50th percentile). Prunes should be introduced every day in three meals. Prunes can be chopped or grinded before eating them. They can be eaten alone or child may eat them as a part of bigger meal (which is preferred version). Prunes can be introduced with yogurt, cereals, nuts and seeds as a morning meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol 4000
Description: Patients will receive PEG at dose 0,5 g/kg/d once daily orally, for 4 weeks.
Study: NCT01587092

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WorkStation
Description: Participants will be asked to attend 2 scheduled sessions per day of treadmill walking, which will replace their sitting desk time. Participants will complete 2 sessions per day for 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Working Condition
Description: Participants will be asked to continue working at their desk in their usual manner.